Cizzle Biotechnology Holdings PLC (CIZ) Price & Analysis

CIZ Stock Chart & Stats

GBX 1.10-GBX 0.05(-4.35%)

At close: Oct 30 4:00 PM EDT

Day’s Range: GBX 1.09 - GBX 1.20
52-Week Range: GBX 0.90 - GBX 3.90
Previous Close: GBX 1.15
Volume: 400.24K
Average Volume (3M): 1.35M
Market Cap: GBP 5.28M
Enterprise Value: GBP 10.43M
Total Cash (Recent Filing): GBP 81.00K
Total Debt (Recent Filing): GBP 0
Price to Earnings (P/E): ―
Beta: -0.91
Next Earnings: May 05, 2027
EPS Estimate: N/A
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Bulls Say, Bears Say

Bulls Say

Focused Diagnostic Opportunity

The company is concentrated on a defined diagnostic application with potentially meaningful clinical value: earlier lung-cancer detection. A focused biomarker-based platform can support differentiated product development and create a clear pathway toward validation, regulatory progress, and eventual commercialization.

Potential Partnership-led Commercialization

A partnership-led model could allow the company to commercialize its technology through organizations that already possess manufacturing, distribution, and healthcare access. If clinical and regulatory milestones are achieved, licensing, milestone, and royalty structures could provide scalable income without requiring a large internal commercial infrastructure.

Low Reported Debt

Minimal reported debt reduces interest obligations and avoids the immediate refinancing pressure associated with highly leveraged businesses. This gives management more flexibility to direct available capital toward research, validation, and regulatory activities, although it does not remove the need to fund continuing operating losses.

Bears Say

Pre-commercial Revenue Position

The absence of reported revenue indicates that the business has not yet demonstrated commercial adoption or recurring income from its diagnostic technology. Until validation, regulatory progress, and market launch translate into sales or licensing receipts, financial performance remains dependent on external funding and future execution.

Persistent Cash Burn

Continually negative operating cash flow shows that current activities consume cash rather than generate it. This increases dependence on financing or other capital sources to sustain research and development, and can constrain the company’s ability to pursue validation and commercialization if funding conditions become less supportive.

Deteriorating Balance Sheet

Negative equity and a sharply shrinking asset base indicate that accumulated losses have materially weakened the company’s financial foundation. Reduced capital reserves limit resilience and strategic flexibility, while the deterioration increases the importance of securing additional funding or achieving commercialization before resources are further depleted.

Cizzle Biotechnology Holdings PLC News

Cizzle Biotechnology Gains Industry Recognition for Early Lung Cancer Test

Cizzle Biotechnology Holdings PLC ( ($GB:CIZ) ) has shared an announcement. Cizzle Biotechnology Holdings PLC, a UK-based developer of blood-based diagnostics for early cancer detection, is advancing commercialisation of its

1w agoCIZ E7F0

Cizzle Biotechnology Restructures U.S. Royalty Deal as Lung Cancer Test Rollout Accelerates

Cizzle Biotechnology Holdings PLC ( ($GB:CIZ) ) has provided an update. Cizzle Biotechnology has validated its CIZ1B lung cancer biomarker test in a CLIA-accredited U.S. laboratory and is expanding access

2w agoCIZ E7F0

Cizzle Biotechnology Enters Commercial Phase as U.S. Lung Cancer Test Wins CLIA Approval

Cizzle Biotechnology Holdings PLC ( ($GB:CIZ) ) has issued an update. Cizzle Biotechnology has transitioned from development to commercialisation after its CIZ1B biomarker blood test for early-stage lung cancer gained

1M agoCIZ E7F0

Cizzle expands U.S. lung cancer test access with new BioBridge lab deal

Cizzle Biotechnology Holdings PLC ( ($GB:CIZ) ) has provided an update. Cizzle Biotechnology’s North American licensee, Cizzle Bio Inc, has signed a strategic laboratory agreement with BioBridge Global’s BBG Advanced

3M agoCIZ E7F0

Cizzle Biotechnology’s Lung Cancer Blood Test Enters Full Commercial Sales in Key Texas Markets

The latest announcement is out from Cizzle Biotechnology Holdings PLC ( ($GB:CIZ) ). Cizzle Biotechnology’s North American partner Cizzle Bio Inc has begun full commercial sales of the CIZ1B biomarker

3M agoCIZ E7F0

Cizzle Biotechnology Enters Commercial Phase With U.S. Lung Cancer Test Accreditation

An announcement from Cizzle Biotechnology Holdings PLC ( ($GB:CIZ) ) is now available. Cizzle Biotechnology has entered a pivotal commercial phase after its CIZ1B blood test for early-stage lung cancer

3M agoCIZ E7F0

Cizzle Biotechnology Appoints Zeus Capital as Sole Corporate Broker

Cizzle Biotechnology Holdings PLC ( ($GB:CIZ) ) just unveiled an announcement. Cizzle Biotechnology Holdings plc is a life sciences company specialising in a proprietary CIZ1B biomarker blood test for the

4M agoCIZ E7F0

Cizzle Biotechnology shareholders back all AGM resolutions, expand board authorities

Cizzle Biotechnology Holdings PLC ( ($GB:CIZ) ) has issued an announcement. Cizzle Biotechnology Holdings reported that all resolutions at its latest annual general meeting were passed by a show of

4M agoCIZ E7F0

Cizzle wins U.S. CLIA approval for CIZ1B early lung cancer blood test

Cizzle Biotechnology Holdings PLC ( ($GB:CIZ) ) just unveiled an announcement. Cizzle Biotechnology has secured CLIA accreditation in the U.S. for its proprietary CIZ1B biomarker blood test, enabling clinical use

4M agoCIZ E7F0

Cizzle Biotechnology Gains Key U.S. Patent for CIZ1B Lung Cancer Test

An announcement from Cizzle Biotechnology Holdings PLC ( ($GB:CIZ) ) is now available. Cizzle Biotechnology has secured a key U.S. patent covering its core methods for measuring the CIZ1B lung

4M agoCIZ E7F0

CIZ FAQ

What was Cizzle Biotechnology Holdings PLC’s price range in the past 12 months?

Cizzle Biotechnology Holdings PLC lowest share price was 0.90 p and its highest was 3.90 p in the past 12 months.

What is Cizzle Biotechnology Holdings PLC’s market cap?

Cizzle Biotechnology Holdings PLC’s market cap is £5.28M.

When is Cizzle Biotechnology Holdings PLC’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Cizzle Biotechnology Holdings PLC’s earnings last quarter?

Cizzle Biotechnology Holdings PLC released its earnings results on Sep 30, 2026. The company reported -0.001 p earnings per share for the quarter.

Is Cizzle Biotechnology Holdings PLC overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does Cizzle Biotechnology Holdings PLC pay dividends?

Cizzle Biotechnology Holdings PLC does not currently pay dividends.

What is Cizzle Biotechnology Holdings PLC’s EPS estimate?

Cizzle Biotechnology Holdings PLC’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Cizzle Biotechnology Holdings PLC have?

Cizzle Biotechnology Holdings PLC has 480,320,340 shares outstanding.

What happened to Cizzle Biotechnology Holdings PLC’s price movement after its last earnings report?

Cizzle Biotechnology Holdings PLC reported an EPS of -0.001 p in its last earnings report. Following the earnings report the stock price went down -8.824%.

Which hedge fund is a major shareholder of Cizzle Biotechnology Holdings PLC?

Currently, no hedge funds are holding shares in GB:CIZ

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description